Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Peginterferon alfa-2a | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2a. |
| Pegfilgrastim | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegfilgrastim. |
| Peginterferon alfa-2b | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2b. |
| Pegaspargase | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegaspargase. |
| Pegademase | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase. |
| Pegvisomant | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegvisomant. |
| Propylene glycol | The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Propylene glycol. |
| Pegaptanib | The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Heptaethylene glycol. |
| Egaptivon pegol | The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Heptaethylene glycol. |
| PEG-uricase | The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Heptaethylene glycol. |
| Peginterferon alfacon-1 | The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Heptaethylene glycol. |
| GlycoPEG-GCSF | The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Heptaethylene glycol. |
| Pegnivacogin | The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Heptaethylene glycol. |
| Pegpleranib | The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Heptaethylene glycol. |
| Pegsunercept | The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Heptaethylene glycol. |
| Polidocanol | The therapeutic efficacy of Polidocanol can be decreased when used in combination with Heptaethylene glycol. |
| Peginesatide | The therapeutic efficacy of Peginesatide can be decreased when used in combination with Heptaethylene glycol. |
| Certolizumab pegol | The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Heptaethylene glycol. |
| Methoxy polyethylene glycol-epoetin beta | The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Heptaethylene glycol. |
| Peginterferon beta-1a | The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Heptaethylene glycol. |
| Pegloticase | The therapeutic efficacy of Pegloticase can be decreased when used in combination with Heptaethylene glycol. |
| Polyethylene glycol | The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Heptaethylene glycol. |
| Antihemophilic factor (recombinant), PEGylated | The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Heptaethylene glycol. |
| Insulin peglispro | The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Heptaethylene glycol. |
| Eptacog alfa pegol (activated) | The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Heptaethylene glycol. |
| Olaptesed Pegol | The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Heptaethylene glycol. |
| Abicipar Pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Heptaethylene glycol. |
| Lexaptepid pegol | The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Heptaethylene glycol. |
| Cepeginterferon alfa-2B | The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Heptaethylene glycol. |
| Pegvaliase | The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Heptaethylene glycol. |
| Pegamotecan | The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Heptaethylene glycol. |
| Lipegfilgrastim | The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Heptaethylene glycol. |
| Nonacog beta pegol | The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Heptaethylene glycol. |
| Damoctocog alfa pegol | The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Heptaethylene glycol. |
| Elapegademase | The therapeutic efficacy of Elapegademase can be decreased when used in combination with Heptaethylene glycol. |
| Rurioctocog alfa pegol | The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Heptaethylene glycol. |